nabu.science
MethodologyAboutContact

 

  • Snapshot
  • Key Claims
  • Strengths & Limitations
  • Commentary
  • From the Authors
  • Author Note / Field Feedback
  • Dimension breakdown
  • Impact Profile
Free · About 5 minutes
Report #NBU-574C58DC·Framework v5.9·Pipeline v0.4·Evaluated 08 Oct 2026·OECD: 3.2 Clinical medicine·Subfield: Virology·Basis: Full text·Type: Observational cohort study

Longitudinal changes in plasma biomarkers of immune activation, neuronal inflammation and injury in persons with HIV initiating ART.

Henderson et al.Henderson, Dutey-Magni, Herrera et al.·2026·HIV medicine·10.1111/hiv.70236 ↗

Primary claim

Plasma biomarkers of brain health improved following 2 years of ART.

Tentative · headline scope exceeds the non-significant primary NfL result and the systemic nature of most measured markers
In brief

Longitudinal biomarker data enrich the HIV treatment evidence base, but the brain-health conclusion overstates a null primary NfL result.

ReliabilityNo concerns4 of 4 checks completeSee what was checked ↓
Possible — the claim's weakest requirement is that the effect exists at all. Experimental. Every point below is traceable to a quoted passage, but this forecast has not yet been validated against known replication outcomes.
Abstract

BACKGROUND: Data on changes in biomarkers of brain health, and their associations with cognitive function in adults commencing either dual- or triple-antiretroviral therapy (ART) are sparse.

METHODS: Plasma biomarkers (neurofilament light [NfL], glial fibrillary acidic protein [GFAP], sCD14, CXCL10, neopterin and IL-6) were measured at baseline and after 96 weeks on ART in individuals randomized to darunavir/ritonavir and either tenofovir-DF/emtricitabine (triple-ART, n = 119) or raltegravir (dual-ART, n = 119) in NEAT-001/ANRS143. Regression models examined associations of baseline and week-96 biomarker concentrations with HIV clinical parameters, composite cognitive test scores (Standardized neuropsychological test [NPZ], 7-domains) and treatment arm.

RESULTS: In 238 individuals, median age was 38 (interquartile range [IQR] 31, 46) years, 87% male and 83% of white ethnicity. Baseline median log10 HIV RNA 4.73 (IQR 4.23, 5.11) copies/mL and CD4 350 (IQR 285, 412) cells/mm3. At baseline, higher biomarker concentrations were associated with lower CD4 (NfL, GFAP, CXCL10; p < 0.03), higher log10 HIV RNA (sCD14, neopterin, CXCL10; p < 0.02) and longer known duration of HIV (sCD14; p = 0.044). At week-96, 94% had plasma HIV <50 copies/mL, and a decline in biomarker concentrations was observed: GFAP -14.4%, sCD14 -6.8%, neopterin -47.4%, CXCL10 -58.8%, IL-6 -29.5% (all p < 0.001) and NfL -4.4% (p = 0.075). NPZ improved by 0.21 mean points. Change in GFAP, CXCL10, sCD14, neopterin and NfL was negatively associated with change in CD4 (all p ≤ 0.002) but not change in NPZ (p > 0.05). A greater decline in neopterin concentration was observed with dual- (-50.2%) versus triple-ART (-44.3%; p = 0.022).

CONCLUSIONS: Plasma biomarkers of brain health improved following ART initiation, associated predominantly with improvements in CD4 count and partly with treatment arm.

Key Claims

Primary finding · Tentative

Plasma biomarkers of brain health improved following 2 years of ART.

Possible — the claim's weakest requirement is that the effect exists at all. Experimental. Every point below is traceable to a quoted passage, but this forecast has not yet been validated against known replication outcomes.

headline scope exceeds the non-significant primary NfL result and the systemic nature of most measured markers

Conclusions
Quote verified
Secondary · Supported

A decline in biomarker concentrations was observed: GFAP -14.4%, sCD14 -6.8%, neopterin -47.4%, CXCL10 -58.8%, IL-6 -29.5% (all p < 0.001) and NfL -4.4% (p = 0.075).

paired measurements support the reported direction, with selection concerns and no untreated comparator limiting interpretation

Abstract, Results; Results, Table 2
Quote verified
Secondary · Supported

Change in GFAP, CXCL10, sCD14, neopterin and NfL was negatively associated with change in CD4 (all p ≤ 0.002) but not change in NPZ (p > 0.05).

reported regressions support the associations, although age-sex adjustment and incomplete cognitive follow-up limit inference

Abstract; Results, Table 3
Quote verified
Secondary · Tentative

A greater decline in neopterin concentration was observed with dual- (-50.2%) versus triple-ART (-44.3%; p = 0.022).

randomization supports comparison, but the isolated exploratory result was underpowered and uncorrected for multiple biomarker tests

Abstract; Results, Table 4
Quote verified
Secondary · Supported

Change in cognitive function was not associated with change in biomarker concentrations.

the reported models were null, but cognitive data were incomplete and differentially available by treatment arm

Conclusions; Results, Table 3
Quote verified

Derived from the full evaluation — not a separate score.

Strengths · Limitations

Strengths

#methodological rigour

Randomized regimen comparison within longitudinal follow-up

The biomarker analysis follows participants for 96 weeks within a randomized dual-versus-triple ART trial, allowing a stronger regimen comparison than an uncontrolled switching cohort.

↳ Methods, Study Design and Participants; Statistical Analysis

#methodological rigour

Prespecified hierarchy and transparent assay methods

NfL and GFAP were designated primary biomarkers, other objectives were identified as exploratory, and laboratory procedures include plate randomization, duplicate measurements, and Simoa quality-control coefficients.

↳ Laboratory Analyses; Statistical Analysis

#positioning

Substantive engagement with contrasting evidence

The Discussion compares the results with treatment-initiation and switching studies, including findings of increased, unchanged, and reduced inflammatory markers across different dual regimens.

↳ Discussion, paragraph 2

Limitations

#reporting

Brain-health headline exceeds primary evidence

The conclusion that brain-health biomarkers improved encompasses a non-significant NfL change and several systemic immune markers, while biomarker change was not associated with cognitive change.

↳ Abstract; Results, Tables 2–3; Conclusions

#methodological rigour

Selection and missingness remain insufficiently tested

Only 238 of 805 trial participants had paired samples, included participants differed on CD4, and cognitive data availability differed by randomized arm despite an MCAR assumption and no reported sensitivity analysis.

↳ Statistical Analysis; Results, Participant Characteristics; Tables S1–S2

#contribution

Exploratory arm signal lacks multiplicity control

The neopterin difference was one exploratory comparison across multiple biomarkers, the study was not powered for biomarker arm effects, and the result was nonetheless carried into the conclusion.

↳ Statistical Analysis; Results, Table 4; Discussion, paragraph 2; Conclusions

Does this match your read? Add your assessment ↓

Nabu Commentary

The study benefits from a prespecified biomarker hierarchy, detailed laboratory reporting, and a randomized comparison of treatment regimens. Its descriptive longitudinal findings are informative, particularly for systemic immune activation markers, but the MCAR assumption and selected paired-sample cohort introduce uncertainty. The principal framing problem is that “brain health improved” extends beyond the non-significant NfL result and the absence of any association with cognitive change. The neopterin arm difference is best treated as hypothesis-generating because it was exploratory, uncorrected for multiplicity, and explicitly underpowered.

Evaluate another paper

Free · About 5 minutes · Research preview

Author Note / Field Feedback

Nabu’s assessment, alongside the field’s view.

Are you an author of this paper?

Dimension breakdown

Evidence Score

Out of 5
012345
3.1±0.2

Contribution
3.3

The study adds 96-week plasma biomarker data from treatment-naive adults and a randomized dual-versus-triple ART comparison. The advance remains incremental because NfL did not change significantly and the treatment-arm signal was confined to exploratory neopterin analysis.

Introduction; Statistical Analysis; Results, Tables 2–4

“However, no statistically significant decline in NfL concentrations was observed.”

Methodological Rigour
2.8

The analysis uses a prespecified hierarchy, transformed biomarker models, ANCOVA for randomized-arm comparisons, and documented assay procedures. Confidence is reduced by the unsupported MCAR assumption, biomarker-cohort selection, unequal cognitive follow-up, and lack of multiplicity control for exploratory tests.

Laboratory Analyses; Statistical Analysis; Results, Participant Characteristics

“Data were assumed to be missing completely at random.”

Reporting
3.2

The methods and numerical findings are presented in a followable sequence, including the non-significant NfL estimate. The headline description of broad improvement in brain-health biomarkers is stronger than the reported primary and cognitive findings support.

Abstract; Results, Table 2; Conclusions

“Plasma biomarkers of brain health improved following 2 years of ART.”

Positioning
3.4

The Discussion engages relevant dual- and triple-ART studies, contrasting findings, generalizability, cognitive attrition, absent CSF sampling, and the non-preferred regimen. Selection effects and the implications of having no non-initiation comparator are not fully traced into the central interpretation.

Discussion, paragraphs 1–3 and limitations paragraph

“We were not able to control for potential confounders such as lifestyle factors, comorbidities or ART-related metabolic effects.”

Reliability

No concerns4 of 4 checks


Results checkClean

The reported numbers and statistics are consistent with the stated results.

Reporting and transparencyClean

No existing reporting or transparency concern warrants retention.

Conflict of interest: declared · Ethics approval: declared · Data availability: declared · Code availability: not stated

Reference IntegrityClean

35 references in manuscript 33 of 33 checkable references found in an index 2 are books, websites or datasets — counted, but not index-checkable

References not verified automatically are resolved manually within 24 hours.

Post-Publication RecordClean

No retraction or expression of concern found in Crossref (includes Retraction Watch).

Last checked: 17 Oct 2026

Sources: Crossref (incl. Retraction Watch) ✓

Impact Profile

Impact areaHealth · Infection · HIV/AIDS
Type of advanceEmpirical
Route to useNot stated
AdvanceExtends
BeneficiariesLarge
CitationsToo early
Policy · patentNot yet traced
ReachedNot reachedNot assessable or unverified
ReadinessValidated
Foundational
Controlled
Piloted
Validated
Implementable
FoundationalImplementable

The primary claim is supported by longitudinal measurements in a randomized multicentre trial across 15 European countries with 96 weeks of follow-up, an independent multi-site setting.

The paper concludes the clinical significance of biomarker changes remains unclear and calls only for further research in larger trials, stating no real-world use of its own findings.

Pathway

HIV clinicians and trial teams could use plasma biomarkers to monitor brain health and CNS safety of ART regimens where cerebrospinal fluid sampling is impractical.

Barrier

The paper itself finds no association between biomarker change and cognitive change, leaving the clinical significance of these biomarker improvements unclear.

Evaluated 13 Nov 2026 · GBD 2023 · glm_v1_3_3 · impact_profile_v1_3_3

Report an issue →

AI-generated, human-governed. Something look off? Contact us to request a review.

Keep reading

Related evaluations

Other papers Nabu has evaluated blind, starting with the same field.

  1. Neuroaxonal Injury in Acute HIV Infection and Following Immediate Antiretroviral Therapy

    Chan, Sacdalan, Pinyakorn, et al. · 2025 · Neurology and psychiatry

    Primary claim

    CSF NFL was elevated (ie, >UNL) in 15%, 8%, and 7% of RV254 participants at weeks 0, 24, and 48 + respectively, versus 2% among PWoH.

    Supported
    Evidence Score
    3.0±0.2
    Reliability
    Caveats
  2. (Dis)similarities between the Decidual and Tumor Microenvironment

    Krstic, Deutsch, Fuchs, et al. · 2022 · Basic medicine

    Primary claim

    Trophoblast and tumor cells are both supported by an abetting microenvironment (Figure 1) that influences/regulates invasion, angiogenesis, and immune tolerance/evasion, among others.

    Supported
    Evidence Score
    3.2±0.1
    Reliability
    Caveats
  3. Early human trophoblast development: from morphology to function

    Gauster, Moser, Wernitznig, et al. · 2022 · Basic medicine

    Primary claim

    It seems as if only this multinucleated layer [the primitive syncytiotrophoblast] is able to penetrate the uterine epithelium and allows embedding of the embryo into the uterine stroma

    Tentative
    Evidence Score
    3.4±0.1
    Reliability
    No concerns

How the rubric works →